Turnstone BiologicsTSBX
About: Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
Employees: 82
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
15% more funds holding
Funds holding: 39 [Q1] → 45 (+6) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
2.99% less ownership
Funds ownership: 54.01% [Q1] → 51.03% (-2.99%) [Q2]
5% less capital invested
Capital invested by funds: $32.7M [Q1] → $30.9M (-$1.77M) [Q2]
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
B of A Securities Charlie Yang 100% 1-year accuracy 1 / 1 met price target | 5%downside $0.50 | Neutral Downgraded | 14 Oct 2024 |
B of A Securities Geoff Meacham 47% 1-year accuracy 8 / 17 met price target | 1,796%upside $10 | Buy Maintained | 19 Aug 2024 |
Piper Sandler Joseph Catanzaro 40% 1-year accuracy 8 / 20 met price target | 611%upside $3.75 | Overweight Maintained | 19 Aug 2024 |
